Single-Cell Level Variability May Help Predict Responses to BRAF Inhibitors in Melanoma

Source: Pharmacy Times, November 2019

New targeted therapy options, such as BRAF and MEK inhibitors, offer advanced treatment for patients with melanoma; however, genetic variability often means that patients will have different therapeutic responses.

A new study published in EBioMedicine provides insight into single-cell level differences that may help predict responses to initial BRAF inhibitor therapy and improve patient outcomes.

Most patients with advanced melanoma will receive immune checkpoint therapy as a frontline treatment.

Read the original full article